Hemoperfusion with Seraph-100 in septic patients removes pathogens and improves clinical outcomes

Abstract Hemoperfusion (HP) represents a treatment option for sepsis. This study evaluated Seraph-100 in septic patients admitted to the intensive care unit (ICU) after cardiac surgery due to infective endocarditis (IE). Thirteen septic patients were enrolled and treated by Seraph-100 hemoperfusion....

Full description

Saved in:
Bibliographic Details
Main Authors: Antonio Lacquaniti, Antonella Smeriglio, Fabrizio Ceresa, Susanna Campo, Daniele Caruso, Giuseppe Falliti, Erminia La Camera, Francesco Patané, Domenico Trombetta, Paolo Monardo
Format: Article
Language:English
Published: Nature Portfolio 2025-05-01
Series:Scientific Reports
Subjects:
Online Access:https://doi.org/10.1038/s41598-025-01280-z
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849731790067990528
author Antonio Lacquaniti
Antonella Smeriglio
Fabrizio Ceresa
Susanna Campo
Daniele Caruso
Giuseppe Falliti
Erminia La Camera
Francesco Patané
Domenico Trombetta
Paolo Monardo
author_facet Antonio Lacquaniti
Antonella Smeriglio
Fabrizio Ceresa
Susanna Campo
Daniele Caruso
Giuseppe Falliti
Erminia La Camera
Francesco Patané
Domenico Trombetta
Paolo Monardo
author_sort Antonio Lacquaniti
collection DOAJ
description Abstract Hemoperfusion (HP) represents a treatment option for sepsis. This study evaluated Seraph-100 in septic patients admitted to the intensive care unit (ICU) after cardiac surgery due to infective endocarditis (IE). Thirteen septic patients were enrolled and treated by Seraph-100 hemoperfusion. Fiftenne patients, not treated by HP, represented a control group. Pathogens were assessed before (T0) and after 4 h of HP treatment (T4). The difference between the two- quantification cycle (Cq) values (T0 and T4), namely ∆Cq at the polymerase chain reaction, was a surrogate marker of pathogen removal. The bacterial load decreased after Seraph-100 HP, with a mean ∆Cq values of 4.6 ± 2.4, as corroborated by conventional haemoculture’s results. Field Emission Scanning Electron Microscopy analyses confirm the Seraph’ adsorptive properties. Procalcitonin, C reactive protein and lactates significantly decreased, with a reduced ICU stay in the Seraph group. After HP, only 15% of patients had AKI requiring renal replacement therapy (RRT), significantly lower than that found in the control group (40%). The Seraph-100 HP induces a decrease of vasopressor doses, a hemodynamic stability and a reduction of AKI and RRT, improving the clinical course, reflected as a reduced ICU stay.
format Article
id doaj-art-59b04233eef54b94bc0249f74df506f7
institution DOAJ
issn 2045-2322
language English
publishDate 2025-05-01
publisher Nature Portfolio
record_format Article
series Scientific Reports
spelling doaj-art-59b04233eef54b94bc0249f74df506f72025-08-20T03:08:25ZengNature PortfolioScientific Reports2045-23222025-05-0115111310.1038/s41598-025-01280-zHemoperfusion with Seraph-100 in septic patients removes pathogens and improves clinical outcomesAntonio Lacquaniti0Antonella Smeriglio1Fabrizio Ceresa2Susanna Campo3Daniele Caruso4Giuseppe Falliti5Erminia La Camera6Francesco Patané7Domenico Trombetta8Paolo Monardo9Nephrology and Dialysis Unit, Papardo HospitalDepartment of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of MessinaCardiac Surgery Unit, Papardo HospitalNephrology and Dialysis Unit, Papardo HospitalClinical Pathology Unit, Papardo HospitalClinical Pathology Unit, Papardo HospitalDepartment of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of MessinaCardiac Surgery Unit, Papardo HospitalDepartment of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of MessinaNephrology and Dialysis Unit, Papardo HospitalAbstract Hemoperfusion (HP) represents a treatment option for sepsis. This study evaluated Seraph-100 in septic patients admitted to the intensive care unit (ICU) after cardiac surgery due to infective endocarditis (IE). Thirteen septic patients were enrolled and treated by Seraph-100 hemoperfusion. Fiftenne patients, not treated by HP, represented a control group. Pathogens were assessed before (T0) and after 4 h of HP treatment (T4). The difference between the two- quantification cycle (Cq) values (T0 and T4), namely ∆Cq at the polymerase chain reaction, was a surrogate marker of pathogen removal. The bacterial load decreased after Seraph-100 HP, with a mean ∆Cq values of 4.6 ± 2.4, as corroborated by conventional haemoculture’s results. Field Emission Scanning Electron Microscopy analyses confirm the Seraph’ adsorptive properties. Procalcitonin, C reactive protein and lactates significantly decreased, with a reduced ICU stay in the Seraph group. After HP, only 15% of patients had AKI requiring renal replacement therapy (RRT), significantly lower than that found in the control group (40%). The Seraph-100 HP induces a decrease of vasopressor doses, a hemodynamic stability and a reduction of AKI and RRT, improving the clinical course, reflected as a reduced ICU stay.https://doi.org/10.1038/s41598-025-01280-zSeraph-100HemoperfusionSepsisAKIICU stay
spellingShingle Antonio Lacquaniti
Antonella Smeriglio
Fabrizio Ceresa
Susanna Campo
Daniele Caruso
Giuseppe Falliti
Erminia La Camera
Francesco Patané
Domenico Trombetta
Paolo Monardo
Hemoperfusion with Seraph-100 in septic patients removes pathogens and improves clinical outcomes
Scientific Reports
Seraph-100
Hemoperfusion
Sepsis
AKI
ICU stay
title Hemoperfusion with Seraph-100 in septic patients removes pathogens and improves clinical outcomes
title_full Hemoperfusion with Seraph-100 in septic patients removes pathogens and improves clinical outcomes
title_fullStr Hemoperfusion with Seraph-100 in septic patients removes pathogens and improves clinical outcomes
title_full_unstemmed Hemoperfusion with Seraph-100 in septic patients removes pathogens and improves clinical outcomes
title_short Hemoperfusion with Seraph-100 in septic patients removes pathogens and improves clinical outcomes
title_sort hemoperfusion with seraph 100 in septic patients removes pathogens and improves clinical outcomes
topic Seraph-100
Hemoperfusion
Sepsis
AKI
ICU stay
url https://doi.org/10.1038/s41598-025-01280-z
work_keys_str_mv AT antoniolacquaniti hemoperfusionwithseraph100insepticpatientsremovespathogensandimprovesclinicaloutcomes
AT antonellasmeriglio hemoperfusionwithseraph100insepticpatientsremovespathogensandimprovesclinicaloutcomes
AT fabrizioceresa hemoperfusionwithseraph100insepticpatientsremovespathogensandimprovesclinicaloutcomes
AT susannacampo hemoperfusionwithseraph100insepticpatientsremovespathogensandimprovesclinicaloutcomes
AT danielecaruso hemoperfusionwithseraph100insepticpatientsremovespathogensandimprovesclinicaloutcomes
AT giuseppefalliti hemoperfusionwithseraph100insepticpatientsremovespathogensandimprovesclinicaloutcomes
AT erminialacamera hemoperfusionwithseraph100insepticpatientsremovespathogensandimprovesclinicaloutcomes
AT francescopatane hemoperfusionwithseraph100insepticpatientsremovespathogensandimprovesclinicaloutcomes
AT domenicotrombetta hemoperfusionwithseraph100insepticpatientsremovespathogensandimprovesclinicaloutcomes
AT paolomonardo hemoperfusionwithseraph100insepticpatientsremovespathogensandimprovesclinicaloutcomes